Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.

Trial Details

NCT ID
NCT06121180
Phase
PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • ZIV-Aflibercept
  • Cemiplimab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Tampa, Florida, United States|27.94752,-82.45843
  • Chicago, Illinois, United States|41.85003,-87.65005
  • New Hyde Park, New York, United States|40.7351,-73.68791

Key Eligibility Criteria

  • Provision of signed and dated informed consent form.
  • Male or female, aged \>/= 18 years old.
  • Life expectancy of greater than 3 months in the opinion of the investigator.
  • Must be willing and able to provide informed consent signed by study patient or legally acceptable representative, as specified by health authoriti…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →